StockData
Kiora Pharmaceuticals Inc logo

Kiora Pharmaceuticals Inc (KPRX) stock

KPRXNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as KPHMW
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$0.82−0.11 (-11.31%)

Close on Nov 18, 2026Market cap $3.65MP/E –Yield –

Kiora Pharmaceuticals free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Kiora Pharmaceuticals's free cash flow for the twelve months ending Jun 30, 2026 was -$8.61M. For fiscal 2025 it was -$10.07M, down 217.8% from the year before. The highest annual figure on record is $8.55M in fiscal 2024.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$10.07M-217.8%
FY2024Dec 31, 2024$8.55M–
FY2023Dec 31, 2023-$9.56M–
FY2022Dec 31, 2022-$10.43M–
FY2021Dec 31, 2021-$10.74M–
FY2020Dec 31, 2020-$7.34M–
FY2019Dec 31, 2019-$8.15M–
FY2018Dec 31, 2018-$10.86M–
FY2017Dec 31, 2017-$6.51M–
FY2016Dec 31, 2016-$8.41M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$1.92M–
Q1 FY2026Mar 31, 2026-$3.17M–
Q4 FY2025Dec 31, 2025-$2.26M–
Q3 FY2025Sep 30, 2025-$1.27M-238.4%
Q2 FY2025Jun 30, 2025-$3.84M–
Q1 FY2025Mar 31, 2025-$2.70M–
Q4 FY2024Dec 31, 2024-$2.21M–
Q3 FY2024Sep 30, 2024$920.06K–
Q4 FY2023Dec 31, 2023-$2.58M–
Q3 FY2023Sep 30, 2023-$2.52M–
Q4 FY2021Dec 31, 2021-$2.92M–
Q3 FY2021Sep 30, 2021-$2.27M–
Q2 FY2021Jun 30, 2021-$2.92M–
Q1 FY2021Mar 31, 2021-$2.63M–
Q4 FY2019Dec 31, 2019-$2.59M–
Q4 FY2018Dec 31, 2018-$2.00M–
Q4 FY2017Dec 31, 2017-$1.49M–

More Kiora Pharmaceuticals figures

See a number that looks wrong?